Filtering by:
Chronic Lymphocytic Leukemia (CLL)FDA Approves Lumoxiti (Moxetumomab Pasudotox) for Hairy Cell Leukemia
The US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with hairy cell leukemia (HCL) that did not get better with at least 2 different previous treatments or got better but then came back.
Leukemia Survivor: ‘Every Day is a Day of Hope’
Barbara Borrell’s health problems began the day she was born in 1942 when she was diagnosed with diabetes. For the next 50 years she made nutrition and exercise a priority. But in 1993, she was diagnosed with chronic lymphocytic leukemia.
New Cancer Drug Approvals From 2016
In 2016, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
FDA Approves Venclexta (Venetoclax) for a Type of Chronic Lymphocytic Leukemia
The US Food and Drug Administration (FDA) has approved a new targeted therapy for a certain type of chronic lymphocytic leukemia (CLL).
FDA Approves Idelalisib (Zydelig) for Leukemia and Lymphoma
The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for people with relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma (another type of non-Hodgkin lymphoma).
FDA Approves Imbruvica (Ibrutinib) for Chronic Lymphocytic Leukemia
The US Food and Drug Administration has approved the use of Imbruvica (ibrutinib) to treat some people with chronic lymphocytic leukemia (CLL).
Study Shows Experimental Drug Idelalisib Effective Against Chronic Lymphocytic Leukemia
A study of idelalisib finds that this experimental targeted therapy drug may effectively treat chronic lymphocytic leukemia (CLL) patients without the need for chemotherapy.